日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies

NLRP3候选药物临床开发筛选:来自现有技术和新兴技术的经验教训

Tengesdal, Isak W; Banks, Migachelle; Dinarello, Charles A; Marchetti, Carlo

NLRP3 and cancer: Pathogenesis and therapeutic opportunities

NLRP3与癌症:发病机制和治疗机遇

Tengesdal, Isak W; Dinarello, Charles A; Marchetti, Carlo

Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions

地塞米松和 OLT1177 协同抑制 STAT3 功能,减少黑色素瘤生长

Alberto Dinarello, Taylor S Mills, Isak W Tengesdal, Nicholas E Powers, Tania Azam, Charles A Dinarello

IL-38 Gene Deletion Worsens Murine Colitis

IL-38基因缺失加重小鼠结肠炎

de Graaf, Dennis M; Wang, Ruth X; Amo-Aparicio, Jesús; Lee, J Scott; Dowdell, Alexander S; Tengesdal, Isak W; Marchetti, Carlo; Colgan, Sean P; Joosten, Leo A B; Dinarello, Charles A

Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers

髓系细胞中宿主-NLRP3 炎症小体的激活决定了转移性乳腺癌对抗 PD-1 疗法的反应

Isak W Tengesdal, Suzhao Li, Nicholas E Powers, Makenna May, Charles P Neff, Leo A B Joosten, Carlo Marchetti, Charles A Dinarello

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

靶向肿瘤来源的NLRP3可通过限制髓源性抑制细胞(MDSC)的扩增来减缓黑色素瘤的进展。

Tengesdal, Isak W; Menon, Dinoop R; Osborne, Douglas G; Neff, Charles P; Powers, Nicholas E; Gamboni, Fabia; Mauro, Adolfo G; D'Alessandro, Angelo; Stefanoni, Davide; Henen, Morkos A; Mills, Taylor S; De Graaf, Dennis M; Azam, Tania; Vogeli, Beat; Palmer, Brent E; Pietras, Eric M; DeGregori, James; Tan, Aik-Choon; Joosten, Leo A B; Fujita, Mayumi; Dinarello, Charles A; Marchetti, Carlo

The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity

抗炎细胞因子白细胞介素-37 是训练免疫的抑制剂

Giulio Cavalli, Isak W Tengesdal, Mark Gresnigt, Travis Nemkov, Rob J W Arts, Jorge Domínguez-Andrés, Raffaella Molteni, Davide Stefanoni, Eleonora Cantoni, Laura Cassina, Silvia Giugliano, Kiki Schraa, Taylor S Mills, Eric M Pietras, Elan Z Eisenmensser, Lorenzo Dagna, Alessandra Boletta, Angelo D'

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Dapansutrile,一种口服选择性 NLRP3 炎症小体抑制剂,用于治疗痛风发作:一项开放标签、剂量适应性、概念验证的 2a 期试验

Klück Viola, Jansen Tim L Th A, Janssen Matthijs, Comarniceanu Antoaneta, Efdé Monique, Tengesdal Isak W, Schraa Kiki, Cleophas Maartje C P, Scribner Curtis L, Skouras Damaris B, Marchetti Carlo, Dinarello Charles A, Joosten Leo A B

Role for nuclear interleukin-37 in the suppression of innate immunity

核内白细胞介素-37在抑制先天免疫中的作用

Li, Suzhao; Amo-Aparicio, Jesus; Neff, Charles P; Tengesdal, Isak W; Azam, Tania; Palmer, Brent E; López-Vales, Rubèn; Bufler, Philip; Dinarello, Charles A

The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6

选择性 ROCK2 抑制剂 KD025 可降低人外周血单核细胞中 IL-17 的分泌,且不依赖于 IL-1 和 IL-6

Isak W Tengesdal, David Kitzenberg, Suzhao Li, Melanie S Nyuydzefe, Wei Chen, Jonathan M Weiss, Jingya Zhang, Samuel D Waksal, Alexandra Zanin-Zhorov, Charles A Dinarello